Omü Nöroloji Kliniğinde Botulinum Toksin Uygulamaları: Retrospektif Bir Çalışma

Year 2007, Volume: 24 Issue: 1, 6 - 14, 29.12.2009

H. Türker M. Onar O. Demir G. Tunalı

Abstract

Botulinum Toxin Appliccations in OMU, Department of Neurology: A Retrospective Study


Clostridium botulinum toxin type A blocks the cholinergic conduction at the neuromuscular conjunction by blocking acetylcholine secretion at the presynaptic region and thus produces muscle paralysis. Such effects of the toxin are in use to treat some diseases. The most frequent neurological indications are hemifacial spasm, essential blepharospasm, cervical dystonia, task-specific dystonia and post-stroke spasticity in adults.In this retrospective study, 46 patients who were tracked for botulinum toxin injections in our department between years 2003 and 2006 are reported. Their diagnoses, schemes of therapy, responses to botulinum toxin treatment, side effects, follow-up during injection therapies and subjective evaluations of therapy by patients are presented and discussed p e rta ining the relative literature.



Clostridium botulinum tip A toksini, nöromüsküler kavşakta presinaptik bölgede asetilkolin salınımını ve kolinerjik iletimi bloke ederek kas paralizisine yol açmakta ve bu etkisinden bazı hastalıkların tedavisinde yararlanılmaktadır. Nörolojik uygulamalarda toksinin kullanımı için; hemifasiyal spazm, esansiyel blefarospazm, servikal distoni, taska spesifik distoni ve erişkinde inme sonrası gelişen spastisite gibi endikasyon alanları bulunmaktadır. Bu retrospektif çalışmada, 2003-2006 yılları arasında kliniğimizde izlenen ve botulinum toksin enjeksiyonları uygulanan 46 hastanın tanıları, tedavi şemaları, botulinum toksin tedavisine yanıtları, tedavide karşılaşılan yan etkiler ile hastaların tedavileri boyunca yapılan izlemleri ve tedaviye yanıtın hastalar tarafından sübjektif değerlendirmeleri rapor edilmiş ve tartışılmıştır.

Keywords

-

References

• Costa PG, Aoki L, Saraiva FP, et al. Botulinum toxin in the treatment of facial dystonia: Evaluation of its efficacy and patients’ satisfaction along the treatment. Arq Bras Oftalmol. 2005; 68: 471–474.
• Schellini SA, Matai O, Igami TZ, et al. Essential b l e p h a r o s p a s m and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and l i t e r a t u r e review. Arq Bras Oftalmol. 2006; 69: 23–26. 3. Chang LB, Tsai CP, Liao KK, et al. Use of botulinum toxin A in the treatment of hemifacial spasm and b l epharospasm. Zhonghua Yi Kue Za Zki. 1999; 62: 1–5. 4. Berardelli A, Carta A, Stocchi F, et al. Botulinum A toxin injection in patients with blepharospasm, t o r t i k o l l i s and hemifacial spasm. Hzl J Neurol Sci. 1990; 11: 589–93.
• Tan AK. Botulinum toxin for neurological disorders in a movement disorders clinic in Singapore. Singapore Med J. 1998; 39: 403–5.
• Andrade LA, Borges V, Ferraz HB, et al. Botulinum toxin A: experience in the treatment of 115 patients. Arq Neuropsiquatr. 1997; 55: 553–7.
• Astarloa R, Morales B, Sanchez V, et al. Focal dystonias and facial hemispasm: treatment with botulinum A toxin. Arch Neurobiol. 1991; 54: 44–51.
• Berardelli A, Formica A, Mercuri B, et al. Botulinum toxin treatment in patients with focal dystonia and hemifacial spasm. A multicenter study of the Italian Movement Disorder Group. Ital J Neurol Sci. 1993; 14: 361–7.
• Kwan MC, Ko KF, Chan TP, et al. Treatment of dystonia with botulinum A toxin: a retrospective study of 170 patients. HKMJ. 1998; 4: 279–82.
• Bhatia KP, Münchau A, Thompson PD, et al. Generalized muscular weakness after botulinum toxin injection for dystonia: a report of three cases. J Neurol Neurosurg Psychiatry. 1999; 67: 90–93.
• Park YC, Lim JK, Lee DK, et al. Botulinum: A toxin treatment of hemifacial spasm and blepharospasm. J Korean Med Sci. 1993; 8: 334–340.
• Tan NC, Chan L, Tan EK. Hemifacial spasm and involuntary facial movements. QJ Med. 2002; 95: 493–500.
• Nakamura T, Osawa M, Uchiyama S, Iwata M. Arterial hypertension in patients with left primary hemifacial spasm is associated with neurovascular compression of the left rostral ventrolateral medulla. Eur Neurol 2007; 57: 150–155.
• Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenecity of original versus current b o t u l i n u m toxin in cervical dystonia. Neurology. 2003; 60: 1186–1188
• Lee MC. Spasmotic torticollis: Medical and Botulinum A Toxin Treatment. Yonsei Med J. 1992; 33: 289–293. 16. Durtton JJ. Botulinum-A toxin in the treatment of craniocervical muscle spasm: short and long term, local and systemic effects. Surv Ophtalmol. 1999; 41: 51–65.
• Anderson TJ, Rivest J, Stell R, et al. Botulinum toxin treatment of spasmodic torticollis. J Royal Soc Med. 1992; 85: 524–29.
• Dubinsky RM, Gray CS, Vetere-Overfield B, et al. Electromyographic guidance of botulinum toxin treatm e n t in cervical dystonia. Clin Neuropharmacol. 1991; 14: 262–267.
• D’Costa DF, Abbott RJ. Low dose botulinum toxin in spasmodic torticollis. Journal of the Royal Society of Medicine. 1991; 84: 650–651.
• Van den Berg P, Francart J, Mourin S, et al. Five year experience in the treatment of focal movement disorders with low dose Dysport botulinum toxin. Muscle Nerve. 1995; 18: 720–729.
• Van Rhijn J, Molenaers G, Ceulemans B. Botulinum toxin in the treatment of children and adolescents with an acquired brain injury. Brain Injury. 2005; 19: 331–335.
• Cosgrove AP. Botulinum toxin in the management of cerebral palsy. Eur J Neurol. 1995; 2: 73–80.
• Ward Ab, Molenaers G, Colosimo C, et al. Clinical value of botulinum toxin in neurological indications. Eur J Neurol. 2006; 13: 20–26.
• Eames NW, Baker R, Graham K, et al. The effect of botulinum toxin A on gastrocinemius length: magnitude and duration of response. Dev Med Child Neurol. 1999; 41: 226–232.
• Slawek J, Klimont L. Functional improvement in cerebral palsy patients with botulinum toxin A i n j e ctions – preliminary results. Eur J Neurol. 2003; 10: 313–317.
• Carr LJ, Cosgrove AP, Grigras P, et al. Position paper on the use of botulinum toxin in cerebral palsy. Arch Dis Child. 1998; 79: 271–273.